Selective serotonin reuptake inhibitors in human pregnancy: on the way to resolving the controversy
- PMID: 24321501
- DOI: 10.1016/j.siny.2013.11.007
Selective serotonin reuptake inhibitors in human pregnancy: on the way to resolving the controversy
Abstract
There has been an increase in the use of selective serotonin reuptake inhibitors (SSRIs) during pregnancy. However, in the last 10 years, in spite of a vast literature regarding use in pregnancy there seems to be some confusion as to the possible risk of these drugs, especially related to cardiovascular anomalies. In addition, there are data on developmental follow-up studies that raise the question of possible slight developmental and neurobehavioral problems. The purpose of the present review is therefore to critically summarize the current evidence for the risk/benefit analysis of SSRI use in human pregnancy. Although most studies have not shown an increase in the overall risk of major malformations, several have suggested that the use of SSRIs may be associated with a small increased risk for cardiovascular malformations. However, new compelling evidence shows that this apparent increased risk occurs also in women with untreated depression, highlighting the probable ascertainment bias involved in many of these studies. Persistent pulmonary hypertension of the newborn (PPHN) has also been described with an absolute risk of <1%; however, here too, higher rates were described among offspring of women with untreated depression. Poor neonatal adaptation has been described in up to 30% of neonates exposed to SSRIs late in pregnancy. Of the few postnatal developmental follow-up studies, there are no significant developmental problems. The literature on SSRIs in pregnancy is somewhat confusing but when analysing all prospective cohort data there seems to be no demonstrable increase in the rate of major anomalies or developmental disorders. When evaluating the risk/benefit ratio of SSRI treatment in pregnancy, the risk associated with treatment discontinuation - e.g. higher frequency of relapse, increased risk of preterm delivery and postpartum depression - appear to outweigh the potential, unproven risks of treatment. Moreover, maternal depression may negatively affect the child's development, emphasizing the importance of prevention by appropriate treatment during pregnancy with the least minimal effective dose.
Keywords: Major anomalies; Neonatal effects; Neurodevelopmental effects; Persistent pulmonary hypertension; Selective serotonin reuptake inhibitors (SSRIs).
Copyright © 2014 Elsevier Ltd. All rights reserved.
Similar articles
-
Prenatal exposure to selective serotonin reuptake inhibitors and serotonin norepinephrine reuptake inhibitors and risk for persistent pulmonary hypertension of the newborn: a systematic review, meta-analysis, and network meta-analysis.Am J Obstet Gynecol. 2019 Jan;220(1):57.e1-57.e13. doi: 10.1016/j.ajog.2018.08.030. Epub 2018 Aug 28. Am J Obstet Gynecol. 2019. PMID: 30170040
-
Selective serotonin reuptake inhibitor use in pregnant women; pharmacogenetics, drug-drug interactions and adverse effects.Expert Opin Drug Metab Toxicol. 2018 Mar;14(3):247-259. doi: 10.1080/17425255.2018.1430139. Epub 2018 Jan 24. Expert Opin Drug Metab Toxicol. 2018. PMID: 29345153 Review.
-
Selective Serotonin Reuptake Inhibitors during Pregnancy: Do We Have Now More Definite Answers Related to Prenatal Exposure?Birth Defects Res. 2017 Jul 17;109(12):898-908. doi: 10.1002/bdr2.1078. Birth Defects Res. 2017. PMID: 28714608 Review.
-
Selective serotonin reuptake inhibitors in pregnancy.Curr Med Chem. 2012;19(27):4554-61. doi: 10.2174/092986712803306349. Curr Med Chem. 2012. PMID: 22876893 Review.
-
[Treatment of depressed pregnant women by selective serotonin reuptake inhibitors: risk for the foetus and the newborn].Encephale. 2010 Jun;36 Suppl 2:D133-8. doi: 10.1016/j.encep.2009.06.005. Epub 2009 Sep 19. Encephale. 2010. PMID: 20513456 Review. French.
Cited by
-
Effect of Parenting Interventions on Perinatal Depression and Implications for Infant Developmental Outcomes: A Systematic Review and Meta-Analysis.Clin Child Fam Psychol Rev. 2022 Jun;25(2):316-338. doi: 10.1007/s10567-021-00371-3. Epub 2021 Sep 27. Clin Child Fam Psychol Rev. 2022. PMID: 34580804 Review.
-
Tapering Antidepressants While Receiving Digital Preventive Cognitive Therapy During Pregnancy: An Experience Sampling Methodology Trial.Front Psychiatry. 2020 Oct 22;11:574357. doi: 10.3389/fpsyt.2020.574357. eCollection 2020. Front Psychiatry. 2020. PMID: 33192705 Free PMC article.
-
Gestational Exposure to Serotonin Reuptake Inhibitors and Pregnancy Outcome; Exploring the Role of Bias and Confounders.Curr Neuropharmacol. 2021;19(12):2227-2232. doi: 10.2174/1570159X18666201015161105. Curr Neuropharmacol. 2021. PMID: 33059578 Free PMC article. Review.
-
Epigenetic Mechanisms in the Neurodevelopmental Theory of Depression.Depress Res Treat. 2020 Apr 24;2020:6357873. doi: 10.1155/2020/6357873. eCollection 2020. Depress Res Treat. 2020. PMID: 32373361 Free PMC article. Review.
-
SSRIs and SNRIs (SRI) in Pregnancy: Effects on the Course of Pregnancy and the Offspring: How Far Are We from Having All the Answers?Int J Mol Sci. 2019 May 14;20(10):2370. doi: 10.3390/ijms20102370. Int J Mol Sci. 2019. PMID: 31091646 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical